top of page
image2.png

AAV vectors that are safe and efficient

Innovative Gene Therapy for Hemophilia

and other Human Liver Diseases

transparent background - vector gray

Advancing vector-based gene therapy treatments

Our Platform

Best-in-class delivery system for treating hemophilia and other human liver diseases.

By utilizing proprietary capsid and genome-modified vectors, our technology offers longer-term
therapeutic results at a lower dose and cost
than current alternatives.

AdobeStock_1660183226.jpeg

Hemophilia B & A

Tackling human liver diseases with groundbreaking efficiency

AdobeStock_1284390600.jpeg

Hemophilia B & A

1.3M+ global patients

Affecting more than 1.3 million patients globally, hemophilia B & A are bleeding disorders caused by a lack of specific blood clotting factors primarily produced in the liver.  

 

Hemophilia A, the more common form, affects about 1 in 5,000 males and involves a deficiency of factor VIII (hFVIII).  

 

Hemophilia B, affecting about 1 in 30,000, results from a deficiency of factor IX (hFIX).

bottom of page